loading...| Preferred Name |
cimetidine |
|
| Synonyms |
Tagamet |
|
| Definitions |
A histamine H(2)-receptor antagonist. Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production. Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C374" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C374" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000039185 |
|
| altLabel |
Tagamet N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine |
|
| CAS Registry |
51481-61-9 |
|
| Component of | ||
| cui |
C0592157 C0008783 |
|
| definition |
A histamine H(2)-receptor antagonist. Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production. Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C374" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C374" NCI Thesaurus) |
|
| Legacy PDQ ID |
1804 |
|
| LT |
TRD |
|
| NCI ID |
C374 |
|
| notation |
CDR0000039185 |
|
| NSC Code |
335308 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
cimetidine |
|
| tui |
T109 T121 |